PharmaShots | Incisive News in 3 Shots

Subscribe Now

Inventiva

Inventiva and Hepalys Pharma Enters into Exclusive Licensing Agreement to Develop and Commercialize Lanifibranor to Treat NASH in Japan and South Korea

Inventiva and Hepalys Pharma Enters into Exclusive Licensing Agreement to Develop and Commercialize Lanifibranor to Treat NASH in...

September 21, 2023

Inventiva Receives a Financing of ~$38.79M from Investors for the Development of Its Pipeline

Inventiva Receives a Financing of ~$38.79M from Investors for the Development of Its Pipeline

August 31, 2023

Inventiva Reports Investigator-Initiated P-II Trial Results of Lanifibranor for Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Inventiva Reports Investigator-Initiated P-II Trial Results of Lanifibranor for Type 2 Diabetes and Nonalcoholic Fatty Liver Disea...

June 14, 2023

Inventiva Entered into a License and Collaboration Agreement with Sino Biopharm to Develop and Commercialize Lanifibranor in Greater China

Inventiva Entered into a License and Collaboration Agreement with Sino Biopharm to Develop and Commercialize Lanifibranor in Great...

September 23, 2022

Inventiva Reports the US FDA’s Acceptance of IND for Review of Lanifibranor and Empagliflozin for the Treatment of NASH and T2D

Inventiva Reports the US FDA’s Acceptance of IND for Review of Lanifibranor and Empagliflozin for the Treatment of NASH and T2D

March 9, 2022

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

March 11, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us